{
    "root": "83916eb5-a9d5-40ea-980a-0a76180a1a9c",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "levetiracetam",
    "value": "20240506",
    "ingredients": [
        {
            "name": "LEVETIRACETAM",
            "code": "44YRR34555",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_6437"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15377"
        },
        {
            "name": "SODIUM CHLORIDE",
            "code": "451W47IQ8X",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_26710"
        },
        {
            "name": "ACETIC ACID",
            "code": "Q40Q9N063P",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_15366"
        },
        {
            "name": "SODIUM ACETATE",
            "code": "4550K0SC9B",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_32954"
        }
    ],
    "indications": {
        "text": "levetiracetam sodium chloride injection indicated adjunct therapy adults ( \u226516 years age ) following seizure types oral temporarily feasible : \u2022 partial-onset seizures ( 1.1 ) \u2022 myoclonic seizures patients juvenile myoclonic epilepsy ( 1.2 ) \u2022 primary generalized tonic-clonic seizures ( 1.3 )",
        "doid_entities": [
            {
                "text": "juvenile myoclonic epilepsy (DOID:4890)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4890"
            },
            {
                "text": "myoclonic epilepsy (DOID:308)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_308"
            },
            {
                "text": "epilepsy (DOID:1826)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1826"
            }
        ],
        "orphanet_entities": []
    },
    "contraindications": {
        "text": "\u2022 intravenous infusion ( 2.1 ) \u2022 dilute prior ( 2.1 ) \u2022 administer dose-specific bag intravenously 15-minutes ( 2.1 ) initial exposure levetiracetam \u2022 partial-onset seizures : initial dose 500 mg twice daily . increase 500 mg twice daily every 2 weeks maximum recommended dose 1500 mg twice daily ( 2.2 ) . \u2022 myoclonic seizures patients juvenile myoclonic epilepsy : initial dose 500 mg twice daily . increase 500 mg twice daily every 2 weeks recommended dose 1500 mg twice daily . ( 2.2 ) . \u2022 primary generalized tonic-clonic seizures : initial dose 500 mg twice daily . increase 500 mg twice daily every 2 weeks recommended dose 1500 mg twice daily . ( 2.2 ) . switching oral levetiracetam : total daily dosage/frequency levetiracetam injection equivalent oral levetiracetam ( 2.3 , 2.4 ) . renal impairment : dose adjustment necessary based creatinine clearance ( 2.5 ) .",
        "doid_entities": [
            {
                "text": "juvenile myoclonic epilepsy (DOID:4890)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_4890"
            },
            {
                "text": "myoclonic epilepsy (DOID:308)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_308"
            },
            {
                "text": "epilepsy (DOID:1826)",
                "doid_id": "http://purl.obolibrary.org/obo/DOID_1826"
            }
        ],
        "orphanet_entities": []
    },
    "warningsAndPrecautions": null,
    "adverseReactions": "levetiracetam sodium chloride injection contraindicated patients hypersensitivity levetiracetam . included anaphylaxis angioedema [ ( 5.3 ) ] .",
    "indications_original": "Levetiracetam in Sodium Chloride Injection is indicated for adjunct therapy in adults (\u226516 years of age) with the following seizure types when oral administration is temporarily not feasible: \u2022 Partial-onset seizures ( 1.1 ) \u2022 Myoclonic seizures in patients with juvenile myoclonic epilepsy ( 1.2 ) \u2022 Primary generalized tonic-clonic seizures ( 1.3 )",
    "contraindications_original": "\u2022 For intravenous infusion only ( 2.1 ) \u2022 Do not dilute prior to its use ( 2.1 ) \u2022 Administer dose-specific bag intravenously over 15-minutes ( 2.1 ) Initial Exposure to Levetiracetam \u2022 Partial-Onset Seizures: Initial dose is 500 mg twice daily. Increase by 500 mg twice daily every 2 weeks to a maximum recommended dose of 1500 mg twice daily ( 2.2 ). \u2022 Myoclonic Seizures in Patients with Juvenile Myoclonic Epilepsy: Initial dose is 500 mg twice daily. Increase by 500 mg twice daily every 2 weeks to the recommended dose of 1500 mg twice daily. ( 2.2 ). \u2022 Primary Generalized Tonic-Clonic Seizures: Initial dose is 500 mg twice daily. Increase by 500 mg twice daily every 2 weeks to the recommended dose of 1500 mg twice daily. ( 2.2 ). Switching from or to oral Levetiracetam: The total daily dosage/frequency of levetiracetam injection should be equivalent to those of oral levetiracetam ( 2.3 , 2.4 ). Renal Impairment: Dose adjustment necessary based on creatinine clearance ( 2.5 ).",
    "adverseReactions_original": "Levetiracetam in Sodium Chloride Injection is contraindicated in patients with a hypersensitivity to levetiracetam. Reactions have included anaphylaxis and angioedema [see Warnings and Precautions (\n                     \n                        5.3)].",
    "drug": [
        {
            "name": "levetiracetam",
            "chebi_id": "http://purl.obolibrary.org/obo/CHEBI_6437"
        }
    ]
}